📊 IONS Key Takeaways
Is IONS a Good Investment? Thesis Analysis
Ionis Pharmaceuticals exhibits severe fundamental deterioration with massive operating losses (-$381.7M) despite 33.8% revenue growth, indicating unprofitable growth driven by R&D-heavy operations rather than sustainable business improvements. The company is burning significant cash (-$320M free cash flow) while carrying high leverage (3.71x debt/equity), raising concerns about long-term viability without major operational restructuring or successful late-stage pipeline commercialization.
Why Buy IONS? Key Strengths
- Strong revenue growth of 33.8% year-over-year demonstrates market demand and commercialization progress
- Adequate liquidity position with $372.3M cash and 3.83x current ratio providing near-term operational runway
- Improved net income loss by 16.0% YoY suggesting operational leverage beginning to develop despite losses
IONS Investment Risks to Consider
- Massive operating losses of -$381.7M with negative operating margin of -187.7% indicating core business is deeply unprofitable
- Negative free cash flow of -$320M coupled with high debt burden of $1.8B creates urgent need for profitability transition or additional capital
- Deteriorating cash burn rate (-$268.6M operating cash outflow) with no clear path to profitability in near term, requiring successful commercialization of pipeline candidates
Key Metrics to Watch
- Operating margin trajectory - must show meaningful improvement toward 0% within 2-3 years
- Free cash flow burn rate - sustainability depends on reducing cash consumption or achieving revenue inflection
- Debt/Equity ratio and cash runway - critical to monitor given current leverage and burn rate
IONS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.83x current ratio provides a solid financial cushion.
IONS Profitability Ratios
IONS vs Healthcare Sector
How IONIS PHARMACEUTICALS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IONS Overvalued or Undervalued?
Based on fundamental analysis, IONIS PHARMACEUTICALS INC shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IONS Balance Sheet & Liquidity
IONS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IONIS PHARMACEUTICALS INC's revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-2.56 indicates the company is currently unprofitable.
IONS Growth Metrics (YoY)
IONS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $133.8M | -$128.6M | $-0.80 |
| Q2 2025 | $225.3M | -$23.4M | $-0.15 |
| Q1 2025 | $119.5M | -$142.8M | $-0.93 |
| Q3 2024 | $133.8M | -$140.5M | $-0.95 |
| Q2 2024 | $188.4M | -$66.3M | $-0.45 |
| Q1 2024 | $119.5M | -$124.3M | $-0.87 |
| Q3 2023 | $144.2M | -$47.0M | $-0.33 |
| Q2 2023 | $133.8M | -$85.3M | $-0.60 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IONS Capital Allocation
IONS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IONIS PHARMACEUTICALS INC (CIK: 0000874015)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IONS
What is the AI rating for IONS?
IONIS PHARMACEUTICALS INC (IONS) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IONS's key strengths?
Claude: Strong revenue growth of 33.8% year-over-year demonstrates market demand and commercialization progress. Adequate liquidity position with $372.3M cash and 3.83x current ratio providing near-term operational runway.
What are the risks of investing in IONS?
Claude: Massive operating losses of -$381.7M with negative operating margin of -187.7% indicating core business is deeply unprofitable. Negative free cash flow of -$320M coupled with high debt burden of $1.8B creates urgent need for profitability transition or additional capital.
What is IONS's revenue and growth?
IONIS PHARMACEUTICALS INC reported revenue of $203.3M.
Does IONS pay dividends?
IONIS PHARMACEUTICALS INC does not currently pay dividends.
Where can I find IONS SEC filings?
Official SEC filings for IONIS PHARMACEUTICALS INC (CIK: 0000874015) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IONS's EPS?
IONIS PHARMACEUTICALS INC has a diluted EPS of $-2.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IONS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IONIS PHARMACEUTICALS INC has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IONS stock overvalued or undervalued?
Valuation metrics for IONS: ROE of -78.0% (sector avg: 15%), net margin of -187.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IONS stock in 2026?
Our dual AI analysis gives IONIS PHARMACEUTICALS INC a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IONS's free cash flow?
IONIS PHARMACEUTICALS INC's operating cash flow is $-268.6M, with capital expenditures of $51.4M. FCF margin is -157.4%.
How does IONS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -187.6% (avg: 12%), ROE -78.0% (avg: 15%), current ratio 3.83 (avg: 2).